Lincoln Pharmaceuticals LimitedQ1 FY27 Results & Financial Update
Lincoln Pharmaceuticals Limited: Q1 FY27 consolidated results and company financials – revenue ₹177.28 Cr, PAT ₹36.23 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Lincoln Pharmaceuticals price & chart
Market price₹545.60
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Lincoln Pharmaceuticals Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Lincoln Pharmaceuticals Limited reported a consolidated revenue from operations of INR 177.28 crore for the quarter ended June 30, 2026 (Q1 FY27). Total income for the period stood at INR 201.55 crore, bolstered by other income components.
Profit before tax (PBT) for the quarter reached INR 47.55 crore, while profit after tax (PAT) settled at INR 36.23 crore. The reported PAT margin for Q1 FY27 stood at 20.44%, reflecting strong bottom-line conversion from top-line operations.
Earnings per share (EPS) for the quarter was reported at INR 18.09, underscoring the earnings generated per equity share during the three-month period.
Financial charges remained modest, with finance costs recorded at INR 0.26 crore, indicating minimal debt servicing pressure on the consolidated entity.
Depreciation and amortization expenses for the quarter were recorded at INR 3.88 crore, reflecting the steady upkeep and wear of the company's fixed asset base.
Tax expenses for the period stood at INR 11.32 crore, representing the statutory provision against pre-tax earnings for the quarter.
Other income contributed significantly to the financial results, coming in at INR 24.27 crore, which supported overall profitability alongside core operational streams.
Lincoln Pharmaceuticals Limited reported its consolidated financial results for the first quarter of fiscal year 2027, covering the period ended 30 June 2026, via official exchange filings.
01 · Business model
What does Lincoln Pharmaceuticals do?
Lincoln Pharmaceuticals Limited operates as a prominent pharmaceutical formulation manufacturer based in India, specializing in a broad range of healthcare products across multiple therapeutic segments.
The company's primary revenue engine stems from the development, production, and marketing of finished dosage forms including tablets, capsules, injectables, syrups, and ointments catering to both domestic and international markets.
Lincoln's business model relies on maintaining diverse manufacturing capabilities and expanding its global footprint through regulatory approvals and exports to various developing and semi-regulated markets.
The company sells its products through institutional channels, distributors, and direct medical representative networks, positioning itself to capture demand across anti-infective, respiratory, gastrointestinal, and pain management segments.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹177.28 Cr |
| Total income | ₹201.55 Cr |
| Profit before tax | ₹47.55 Cr |
| Profit after tax | ₹36.23 Cr |
| EPS | ₹18.09 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 20.4% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 26.8% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹24.26 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
The company generated INR 177.28 crore from primary pharmaceutical operations during the quarter ended June 30, 2026.
Total income reached INR 201.55 crore for Q1 FY27, incorporating operational revenues alongside non-operating income of INR 24.27 crore.
Generated INR 177.28 crore in revenue from operations during Q1 FY27 from pharmaceutical product sales.
Total income was bolstered by INR 24.27 crore of other income, bringing aggregate income to INR 201.55 crore.
What drove margins
Tax provisions of INR 11.32 crore were applied against a PBT of INR 47.55 crore, resulting in an effective tax rate customary for the period.
Finance costs were constrained at INR 0.26 crore, supporting net profitability margins by minimizing debt-servicing overheads.
Tax expenses of INR 11.32 crore and minimal finance costs of INR 0.26 crore shaped the final bottom-line profitability alongside depreciation charges of INR 3.88 crore.
04 · Reported developments
What changed operationally
The company achieved a healthy PAT margin of 20.44% on consolidated operations during Q1 FY27.
The company achieved a PAT of INR 36.23 crore on revenue of INR 177.28 crore, representing a net profit margin exceeding 20%.
05 · Items worth noticing
The line items that can distort a quick read
Other income stood at INR 24.27 crore for the quarter, forming a notable portion of the total income of INR 201.55 crore.
06 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
The consolidated finance cost of INR 0.26 crore indicates a light debt-servicing burden for the quarter.
Finance costs were contained at INR 0.26 crore for the quarter, indicating minimal debt burden.
07 · Beyond the numbers
What changed beyond the numbers
Reported update
XBRL Filing Submission
Submitted structured financial data under IND-AS guidelines to the stock exchange for the quarter ended 30 June 2026.
08 · Key Q&A
The quarter, answered directly
What does Lincoln Pharmaceuticals do?
Lincoln Pharmaceuticals Limited operates as a prominent pharmaceutical formulation manufacturer based in India, specializing in a broad range of healthcare products across multiple therapeutic segments.
What is the clearest takeaway from Q1 FY27?
Lincoln Pharmaceuticals Limited reported a consolidated revenue from operations of INR 177.28 crore for the quarter ended June 30, 2026 (Q1 FY27). Total income for the period stood at INR 201.55 crore, bolstered by other income components.
What drove revenue or demand?
The company generated INR 177.28 crore from primary pharmaceutical operations during the quarter ended June 30, 2026.
What mattered most for margins or profitability?
Tax provisions of INR 11.32 crore were applied against a PBT of INR 47.55 crore, resulting in an effective tax rate customary for the period.
What changed operationally beyond the headline numbers?
Submitted structured financial data under IND-AS guidelines to the stock exchange for the quarter ended 30 June 2026.
What should the next disclosure help confirm?
Track upcoming financial disclosures for FY27 to observe revenue trends and operational margin stability.
09 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
10 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarter Filings: Track upcoming financial disclosures for FY27 to observe revenue trends and operational margin stability.
- 02
Subsequent Quarter Filings: Monitor forthcoming quarterly disclosures for sequential comparisons and operating margin trends in FY27.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.